It is reported that inhibition of ROS suppresses pyroptosis in CS-treated BEC via inhibiting the ROS/TXNIP/NLRP3/caspase-1 pathway, which leads to the amelioration of COPD both in vitro and vivo [7, 41, 89]. Here, NLRP3 is linked to chronic obstructive pulmonary disease.